CLB 2018 Annual Report

F-3 CORE LABORATORIES N.V. CONSOLIDATED BALANCE SHEETS December 31, 2018 and 2017 (In thousands, except share and per share data) 2018 2017 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 13,116 $ 14,400 Accounts receivable, net of allowance for doubtful accounts of $2,650 and $2,590 at 2018 and 2017, respectively 129,157 133,097 Inventories 45,664 33,317 Prepaid expenses 15,351 12,592 Income taxes receivable 13,993 7,508 Other current assets 13,696 6,513 TOTAL CURRENT ASSETS 230,977 207,427 PROPERTY, PLANTAND EQUIPMENT, net 122,917 123,098 INTANGIBLES, net 13,054 9,396 GOODWILL 219,412 179,044 DEFERRED TAX ASSETS, net 11,252 10,719 OTHER ASSETS 51,215 55,128 TOTALASSETS $ 648,827 $ 584,812 LIABILITIES AND EQUITY CURRENT LIABILITIES: Accounts payable $ 41,155 $ 41,697 Accrued payroll and related costs 22,549 28,887 Taxes other than payroll and income 7,488 7,313 Unearned revenues 17,325 12,627 Income taxes payable 2,917 825 Other current liabilities 11,113 9,227 TOTAL CURRENT LIABILITIES 102,547 100,576 LONG-TERM DEBT, net 289,770 226,989 CONTRACT LIABILITIES 1,401 4,442 DEFERRED COMPENSATION 49,359 52,786 DEFERRED TAX LIABILITIES, net 7,634 5,323 OTHER LONG-TERM LIABILITIES 37,216 45,964 COMMITMENTS AND CONTINGENCIES EQUITY: Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding — — Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 44,796,252 issued and 44,316,845 outstanding at 2018 and 44,796,252 issued and 44,184,205 outstanding at 2017 1,148 1,148 Additional paid-in capital 57,438 54,463 Retained earnings 156,130 173,855 Accumulated other comprehensive income (loss) (5,456) (8,353) Treasury shares (at cost), 479,407 at 2018 and 612,047 at 2017 (52,501) (76,269) Total Core Laboratories N.V. shareholders' equity 156,759 144,844 Non-controlling interest 4,141 3,888 TOTAL EQUITY 160,900 148,732 TOTAL LIABILITIES AND EQUITY $ 648,827 $ 584,812 The accompanying notes are an integral part of these Consolidated Financial Statements.